Early Commercialization Zenflow has recently launched the Spring Implant and Delivery System and completed first commercial procedures, signaling readiness for scaled adoption and potential access to hospital systems and urology clinics seeking innovative BPH solutions.

Clinical Validation Positive four-year follow-up data from ongoing trials supports long-term efficacy and safety, creating compelling case for payer discussions, surgeon adoption, and broader KOL engagement to drive referrals and utilization.

Strategic Funding With a total funding stack of eighty-two million dollars and a recent Series C led by Cook Medical among others, Zenflow has financial momentum to scale manufacturing, field teams, and training programs for rapid market penetration.

Target Market The focus on benign prostatic hyperplasia addresses a large patient population with unmet needs who prefer office-based, less invasive procedures, presenting opportunities to partner with urology groups, ambulatory surgery centers, and payer-friendly care pathways.

Industry Fit Zenflow operates in medical device manufacturing with capabilities aligned to adjacent BPH and minimally invasive technologies; potential upsell through collaborations with major players in Olympus, Cook Medical, PROCEPT, or Boston Scientific for distribution, co-development, or integration opportunities.